Opens in a new tab
Thursday, 19 November 2026
EVIDENCE. INTERPRETED.
Advertisement · Remove ads
728 × 90
Clinical Trials

ANKTIVA Plus BCG Outperforms Approved NMIBC Therapies in AUA 2026 Analyses

At the 2026 American Urological Association Annual Meeting, ImmunityBio unveiled comparative analyses of ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer.

Written byDr. Preethi PuttiReviewed byPharmacally Editorial Team20 May 2026 · 2 min read
Fact-Checked
Gemini_Generated_Image_1lw8ct1lw8ct1lw8

ImmunityBio presented new comparative data at AUA 2026 showing ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus BCG delivers longer-lasting responses and fewer adverse events than FDA-approved therapies in BCG-unresponsive NMIBC.

ImmunityBio reported new comparative effectiveness data at the 2026 American Urological Association Annual Meeting showing that ANKTIVA® (nogapendekin alfa inbakicept-pmln; NAI) combined with Bacillus Calmette-Guérin (BCG) delivered longer-lasting responses and favorable safety outcomes in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease.

The analyses compared NAI plus BCG against two FDA-approved therapies: nadofaragene firadenovec-vncg and TAR-200. Both studies used matching-adjusted indirect comparison (MAIC) methods because no head-to-head randomized trials currently exist.

ANKTIVA is a first-in-class IL-15 agonist fusion complex that activates natural killer (NK) cells and CD8+ T cells to strengthen anti-tumor immune activity and sustain immune memory. The therapy targets a major unmet need in BCG-unresponsive NMIBC, where patients often face radical cystectomy after limited bladder-sparing treatment options fail.

In the first analysis, investigators compared individual patient data from the QUILT-3.032 study with aggregate data from the nadofaragene firadenovec trial. After statistical adjustment, NAI plus BCG achieved an anytime complete response rate of 69.7% compared with 53.4% for nadofaragene.

Median duration of complete response reached 22.1 months versus 9.7 months, while cystectomy-free survival improved with a hazard ratio of 0.40. Overall survival did not differ significantly between groups.

A second MAIC analysis compared NAI plus BCG with TAR-200 using data from the SunRISe-1 study. At 12 months, complete response rates numerically favored NAI plus BCG, although the difference was not statistically significant. However, treatment-related adverse events occurred substantially less often with NAI plus BCG, with investigators reporting a 68% reduction in adverse event odds versus TAR-200.

Investigators noted that both analyses carry the limitations inherent to unanchored indirect comparisons, including incomplete alignment of baseline tumor characteristics across trials. Still, sensitivity analyses produced consistent findings across efficacy and safety endpoints.

ImmunityBio said the findings support ANKTIVA plus BCG as a potential immunologic backbone for bladder-preserving treatment strategies while the company continues development efforts tied to recombinant BCG and alternative BCG supply sources amid ongoing U.S. shortages.

Reference

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 – ImmunityBio

Advertisement · Remove ads
728 × 90
Reviewed by the Pharmacally Editorial Team
Every story is checked against primary sources.
Our editorial process →